APLMW (Apollomics) Short Interest


APLMW Apollomics Inc APLMW
31 GF Score
Price $0.01
! 5 Warning Signs
View Full Analysis

What is Apollomics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

APLMW vs TVRD, PLRZ, LSTA: Short Interest Comparison

For the Biotechnology subindustry, Apollomics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apollomics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apollomics's Short Interest distribution charts can be found below:

* The bar in red indicates where Apollomics's Short Interest falls into.


APLMW
31GF Score
Apollomics Inc APLMW
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apollomics Business Description

Other Exchanges APLM:USA
Address 989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
31GF Score

Get the complete analysis for APLMW

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price